Understanding the Study on Cannabinoids and SARS-CoV-2

The video discusses a study on cannabigerolic acid and cannabidiolic acid binding to the SARS-CoV-2 spike protein, potentially preventing the virus from entering cells. The study used advanced scientific techniques but hasn't been tested in vivo. It focused on alpha and beta variants, not Omicron. The acids are not psychoactive like THC and would be administered orally if effective.

What is the potential role of cannabigerolic acid and cannabidiolic acid in relation to SARS-CoV-2?

• They can cure COVID-19 completely.

• They can bind to the virus's spike protein, preventing cell entry.

• They enhance the psychoactive effects of THC.

• They are used in vaccines to boost immunity.

How does the study on cannabinoids differ from the development of vaccines?

• Vaccines create T-cell mediated immunity, while the study has not been tested in vivo.

• The study has been tested in vivo, unlike vaccines.

• The study focuses on Omicron, while vaccines do not.

• Vaccines are less effective than cannabinoids.

What is the implication of the study not being tested in vivo?

• The effectiveness in the human body is still unknown.

• The study has been proven to work in all cases.

• The study is irrelevant to COVID-19 prevention.

• The results are conclusive and ready for public use.

Which variants of the virus were included in the cannabinoid study?

• Alpha and Beta variants

• All known variants

• Omicron variant

• Delta variant

What is a key difference between the cannabinoids studied and THC?

• The cannabinoids are used recreationally.

• The cannabinoids are non-psychoactive and would be given orally.

• The cannabinoids are psychoactive like THC.

• The cannabinoids are more potent than THC.